CorVel Corporation — Form 10-Q Summary
Period: The filing covers the quarter and six months ended September 30, 2019, corresponding to fiscal 2020 Q2. This conflicts with the request metadata of “2018 Q2”; the filing itself is for 2019.
Business context and financial results
CorVel provides managed-care and medical-cost-containment services, principally for workers’ compensation, automobile claims, and group health plans. It reports one operating segment. Patient management includes claims and case management; network solutions includes medical bill review, pharmacy, and related services.
- Quarter: Revenue was $147.0 million, down 0.8% year over year. Gross profit was $32.8 million and gross margin was 22.3%, up from 21.3%. Net income was $12.9 million, up 0.6%; diluted EPS was $0.69 versus $0.67.
- Six months: Revenue was $297.1 million, down 0.5%. Gross profit was $66.0 million and gross margin was 22.2%, up from 21.0%. Net income rose 7.0% to $26.3 million; diluted EPS increased 8.5% to $1.40.
- Operating costs: Quarterly cost of revenue declined 2.2% to $114.1 million, while general and administrative expense rose 9.9% to $16.6 million, primarily from legal and corporate-systems costs. Six-month G&A increased 4.2% to $32.3 million.
- Revenue mix: Quarterly patient management revenue grew 4.1% to $95.7 million; network solutions fell 8.9% to $51.3 million. For six months, patient management rose 8.5% to $195.2 million, while network solutions declined 14.2% to $101.9 million. Management cited fewer pharmacy-service bills reviewed; the quarter’s pharmacy bill count was down 20.5%.
- Cash flow and investment: Six-month operating cash flow was $46.4 million, versus $48.6 million. Capital expenditures were $17.5 million, versus $6.5 million, largely for construction on a Portland-area building. Cash increased by $6.2 million to $97.9 million.
- Liquidity and obligations: Working capital was $86.1 million, down from $98.6 million at March 31, 2019. The company reported no debt at quarter-end. Its $10 million revolving credit facility expired in September 2019 and was not renewed. It recorded $99.6 million of operating lease liabilities under the newly adopted lease standard.
- Capital returns: CorVel repurchased 348,877 shares for $28.3 million during the six months, including 224,466 shares for $19.2 million in the quarter. It repurchased a further 92,052 shares for $7.2 million after quarter-end.
Changes, outlook, and risks
- Despite slightly lower revenue, gross margin improved, reflecting a mix shift that included growth in higher-margin enhanced bill-review services and lower pharmacy activity. Fewer weighted-average shares also supported EPS growth.
- Management said cash on hand and expected internally generated funds should cover obligations, planned repurchases, new services, and development for at least the next 12 months. The filing provides no specific revenue or earnings guidance.
- Adoption of ASC 842 on April 1, 2019 added a $94.4 million right-of-use asset and $99.6 million of lease liabilities at September 30; management said adoption did not affect retained earnings or materially affect income-statement results. The balance-sheet increase versus March includes this accounting change.
- Management cited risks including declining workers’ compensation claims, customer insourcing and competition, lower pharmacy volumes, labor and benefit cost pressure, regulatory changes, litigation, and cybersecurity or systems disruption. It also noted seasonal effects from fewer working days in the third fiscal quarter.
- Ordinary-course litigation is ongoing; management believes any resulting payments will not be material. No material off-balance-sheet arrangements were reported, though customary indemnification obligations may arise. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the reporting-period discrepancy: the filing is for September 30, 2019, not 2018.
- Track whether patient-management growth can offset continued weakness in network solutions, particularly pharmacy services, and whether margin gains persist.
- Review cash conversion, elevated capital spending, lease commitments, and the effects of continuing share repurchases on liquidity.
- Assess the impact of rising legal and corporate-systems expense, as well as management’s expectation that G&A costs will return to historical averages.
- Monitor exposure to declining claims volumes, customer retention and insourcing, regulatory and legal developments, and cybersecurity risks.